Lung Ultrasound to Diagnose COVID-19

Covid-19 Clinical Trial

— COVILUS  

Official title:

Use of Lung Ultrasound in Patients Suspected of COVID-19 Infection in the Emergency Room

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04368338
• Other study ID #: PI2020_843_0030
• Status: Completed
• Start date: April 28, 2020
• Est. completion date: July 20, 2021

Study information

• Verified date: July 2021
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Covid-19 (English acronym meaning coronavirus disease 2019) is an emerging infectious disease caused by a strain of coronavirus called SARS-CoV-2. The current pandemic has resulted in a significant number of admissions in the emergency room (ER) due to suspicion of COVID-19 infection. Use of lung ultrasound is standard practice to diagnose acute respiratory failure in ER. Recently, typical lung ultrasonographic characteristics of COVID-19 disease has been described. During the COVID-19 pandemic, the use of this tool could be of interest in order to allow an early, simple and reliable triage in patients with suspected COVID-19 infection admitted in ER. In addition, the visualization of early signs in specific areas could be a predictive marker of the severity of the disease. The objective of this project will be to study the association between the signs on lung ultrasound and the result of RT-PCR in patients with suspected COVID-19 infection in the ER.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: July 20, 2021
• Est. primary completion date: January 28, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients admitted to Emergency Room for suspicion of COVID-19 infection with has a SARS-CoV-2 RT-PCR test and for whom the emergency doctor decide to perform a lung ultrasound

Exclusion Criteria:

• patients < 18 years of age or under guardianship or curators,

• pregnancy

• poor echogenicity due to the presence of an acoustic barrier (pneumothorax, subcutaneous emphysema, etc.)

• patients with a suspected or proven acute lung disease (pneumonitis, acute respiratory distress syndrome (ARDS))

• chronic interstitial lung disease

• patients who will refuse to give their consent.

Related Conditions & MeSH terms

• Covid-19
• Lung Ultrasound
• Respiratory Complication

Intervention

Diagnostic Test:
• COVID-19 RT-PCR
Polymerase chain reaction tests after reverse transcription for the detection of viral Covid-19 RNA (RT-PCR)

Procedure:
• lung ultrasound
lung ultrasound is standard practice to diagnose acute respiratory failure in Emergency room

Locations

Country	Name	City	State
France	BAR	Amiens

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lung ultrasound/biological correlation research modulating the severity of Covid-19 disease	Polymerase chain reaction tests after reverse transcription for the detection of covid-19 viral RNA will be done as biological test.	6 months